LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Cerus Corp

Cerus Corp

Suletud

Sektor Tervishoid

2.02 -2.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.02

Max

2.03

Põhinäitajad
By Trading Economics
Müük	7M 47M
Aktsiakasum	-0.01
Töötajad	288

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+172.28 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	339M
Eelmine avamishind	4.44
Eelmine sulgemishind	2.02

Uudiste sentiment

By Acuity

50%

94 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 2.355 Toetus ja vastupanu

Cerus Corp Graafik

Seotud uudised

19. märts 2024, 16:12 UTC

Suurimad hinnamuutused turgudel

Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial

Võrdlus sarnastega

Hinnamuutus

Cerus Corp Prognoos

Hinnasiht

By TipRanks

172.28% tõus

12 kuu keskmine prognoos

Keskmine 5.5 USD 172.28%

Kõrge 6 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cerus Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Cerus Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 2.355Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

94 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cerus Corp

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.